...
首页> 外文期刊>BMC research notes >Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia
【24h】

Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia

机译:在埃塞俄比亚西北部的Felege Hiwot转诊医院进行抗病毒治疗的成年人中,免疫恢复的时间和决定因素

获取原文
   

获取外文期刊封面封底 >>

       

摘要

BackgroundCD4 cells are the major targets for human immunodeficiency virus (HIV) and treatment with Antiretroviral Therapy (ART) influences the CD4 cell count of HIV patients. In addition to ART, the time required to reach normal range of CD4 counts (500?cells/mm3) can be affected by clinical, socio-demographic, and behavioral factors. This retrospective cohort study was conducted to determine the incidence of having the normal range of CD4 cell counts and factors that affect the time required to reach this normal range among adult HIV patients who initiated into ART. MethodsData of 4?years were retrospectively retrieved from routinely registered characteristics of 937 ART users enrolled in 2010. Survival time until immunologic recovery and its determinant factors were examined using the frailty model with different parametric distributions alternatively. ResultsMost (80.8%) of the ART attendants had CD4 cell count of 200?cells/mm3 or less at initiation. The overall incidence rate of immunologic recovery was 12.67 persons per 1000 person-months (95% CI 11.30, 14.20). The dependency of frailties of immunologic recovery by residence was statistically significant (Theta?=?0.05, p value?=?0.006). Baseline age (Adjusted Hazard Ratio (AHR)?=?0.98, 95% CI 0.97, 0.99), baseline CD4 count (AHR?=?1.006, 95% CI 1.005, 1.008), and female sex (AHR?=?1.34, 95% CI 1.03, 1.73) were significantly associated with shorter survival time for immunologic recovery. ConclusionHigher baseline CD4 count, lower baseline age, and female sex were positively associated with the time to immunologic recovery, which also dependent on proximity/residence of ART users. Therefore, further scale up of ART services with due emphasis to patients with low CD4 count at baseline particularly for male and older ART users are recommended to reach the normal range of CD4 count in a shorter time of treatment.
机译:背景技术CD4细胞是人类免疫缺陷病毒(HIV)的主要靶标,抗逆转录病毒疗法(ART)的治疗会影响HIV患者的CD4细胞计数。除抗逆转录病毒治疗外,达到CD4计数正常范围(500?cells / mm 3 )所需的时间可能会受到临床,社会人口统计学和行为因素的影响。进行了这项回顾性队列研究,以确定在开始接受抗病毒治疗的成年HIV患者中,CD4细胞计数处于正常范围的发生率以及影响达到该正常范围所需时间的因素。方法回顾性分析2010年登记的937名ART使用者常规登记特征的4年数据。使用脆弱性模型(具有不同的参数分布)检查免疫恢复的生存时间及其决定因素。结果最初接受抗逆转录病毒治疗的大多数(80.8%)的CD4细胞计数为200?cells / mm 3 。免疫恢复的总发生率为每1000人月12.67人(95%CI 11.30,14.20)。滞留性对免疫恢复脆弱性的依赖性在统计学上是显着的(θ= 0.05,p值= 0.006)。基线年龄(调整后的危险比(AHR)?=?0.98,95%CI 0.97,0.99),基线CD4计数(AHR?=?1.006,95%CI 1.005,1.008)和女性(AHR?=?1.34, 95%CI 1.03,1.73)与较短的免疫恢复生存时间显着相关。结论较高的基线CD4计数,较低的基线年龄和女性与免疫恢复时间呈正相关,这也取决于ART使用者的接近度/住院率​​。因此,建议进一步扩大抗病毒治疗服务的规模,尤其是针对基线时CD4计数低的患者,尤其是男性和老年ART用户,以在较短的治疗时间内达到CD4计数的正常范围。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号